Expanded Access Use of Cemiplimab in Patients With Solid Tumors

N/AApproved For MarketingNCT06132191

Regeneron Pharmaceuticals

Overview

Provide expanded access of cemiplimab in patients with solid tumors

Compassionate Use requests are only being considered in response to Individual Patient Investigational New Drug (IND) applications. Availability will depend on location.

Study Type

EXPANDED_ACCESS

Conditions

Non-Small Cell Lung Cancer (NSCLC)Basal Cell Carcinoma (BCC)Cutaneous Squamous Cell Carcinoma (CSCC)

Interventions

CemiplimabDRUG

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.